Development of a surface enhanced Raman scattering (SERS) sensor for point of care therapeutic drug monitoring in canine epilepsy

BBSRC · United Kingdom government procurement

This opportunity is now closed. GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

Closed
Status

Opportunity Overview

Epilepsy is the most prevalent neurological condition in canines, affecting 1.5-2% of dogs. In most cases, canine epilepsy is idiopathic and the condition is still poorly understood. Since epilepsy is incurable, treatment is intended to control the symptoms by reducing frequency and intensity of seizures, while minimizing side effects. Therapeutic drug monitoring is therefore required to ensure the correct quantity of drug is administered and to confirm the efficacy of the drugs with minimal adverse effects. Phenobarbitone is the most commonly prescribed medication for canine epilepsy. Generally, the drug would be monitored by taking blood tests at the beginning of treatment and on occurrence of seizures; however, a quicker and less invasive test could provide a significant step in the understanding of idiopathic epilepsy and in monitoring drug treatment. An ideal route to achieving this would be the development of a point-of-care (POC) sensor that could detect the drug in saliva, allowing regular non-invasive monitoring that could potentially be correlated with circulating levels of the drug in routine blood tests. The POC test would allow closer monitoring of drug levels and the correlation with onset of seizures, while minimizing patient distress.
Surface enhanced Raman scattering (SERS) is an ultrasensitive and highly specific technique that can be used for the label-free quantification of analytes. Since SERS gives molecularly specific vibrational information, analytes can be specifically identified and the unique SERS spectra obtained from individual molecules enables the detection and quantification of multiple targets simultaneously. These attributes make SERS an attractive technique for POC analysis and its use has been demonstrated in various applications from drug analysis to medical diagnosis and in food safety.
The basis of SERS is that an enhancing substrate, usually in the form of metallic nanomaterials, will significantly increase the intrinsic...

Your competitors are watching the same crowded contracts everyone else is. Track live opportunities like this one worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyBBSRC
CountryUnited Kingdom
CategoryPharmaceuticals
PublishedSeptember 30, 2024
Procurement stageActive solicitation
ClosedClosing date not published
StatusClosed — no longer accepting responses
Official sourceView original notice
Last verifiedOctober 10, 2026

Source: UK Research and Innovation (UKRI) — Open Government Licence v3.0.

Browse Similar Open Opportunities in United Kingdom

Purchase, Storage and Emergency Production of Foot and Mouth Antigen and Vaccine
Drug Knowledge Base for Electronic Health and Care Record
Criminal Justice Related Drug and Alcohol Referral Service for Adults
Individual Placement & Support Service (IPS)
Contract for the Provision of Drug, Alcohol and DNA Testing Services
Rough Sleeping Drug and Alcohol Psychology Service
Young People Alcohol & Drug Support Service
SOL Drug & Alcohol Services 2027

See every United Kingdom Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United Kingdom Pharmaceuticals intelligence report in your inbox

A personalized report on United Kingdom Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.